CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
This project addresses drug resistance in cancer by studying the evolution of leukemia stem cells under treatment. It aims to develop more effective therapies for myeloproliferative neoplasms by analyzing the response of these cells to targeted therapies.
Despite decades of research, developing ways to overcome drug resistance in cancer is the most challenging bottleneck for curative therapies.
This is because, in some forms of cancer, the cancer stem cells from which the diseases arise are constantly evolving, particularly under the selective pressures of drug therapies, in order to survive.
The events leading to drug resistance can occur within one or more individual cancer stem cell(s) – and the features of each of these cells need to be studi…
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
United Kingdom, Manchester
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
Guests see up to 5 keywords.
